Medicine

Digital Twin Technology Offers New Opportunities in Medicine

Prof. Dr. Gürkan Ersoy, a faculty member of the Faculty of Medicine at Cyprus International University (CIU) and founder of the Artificial Intelligence in Medicine Platform, stated that digital twin technology in medicine offers new opportunities for developing personalized treatment approaches. Ersoy emphasized that virtual models, continuously updated with data obtained from real patients, can help assess the potential outcomes of different treatment options, while research into the technology's clinical applications is still ongoing.

Explaining that digital twins are virtual representations of physical objects, systems, or processes that are updated with new data, Ersoy noted that this approach is used in medicine to model individuals, their organs, or the progression of diseases. He stated that these models can be developed using data obtained from medical examinations, blood tests, radiological images, and wearable devices. They can then be used to monitor changes in a patient's condition and evaluate different scenarios.

Addressing the potential contributions of digital twin technology to personalized treatment planning, Ersoy pointed out that patients with the same diagnosis may respond differently to treatments due to factors such as age, gender, and underlying health conditions. He explained that examining the potential outcomes of different treatment options using virtual models could support physicians in their decision-making processes. He also noted that this approach has the potential to improve treatment effectiveness and reduce side effects.

Ersoy stated that artificial intelligence, the Internet of Things (IoT), and wearable sensors play important roles in the development of this technology. He noted that research into cardiac modelling and virtual patient models for neurological diseases are among the current examples in this field. However, he emphasized that not all models described as digital twins have reached the same level of maturity and cautioned that research findings should not be interpreted as evidence that the technology is ready for routine clinical use.

Ersoy explained that, for digital twins to be used reliably in healthcare, models must be validated across different patient groups, personal health data privacy must be protected, and different segments of society must be adequately represented. He also stressed the importance of ensuring that responsibility for clinical decisions remains with physicians.

Looking ahead, Ersoy stated that digital twins could support risk assessment for specific organs and diseases, intervention planning, and the selection of treatment options tailored to individual patients. He concluded that developing this technology in line with scientific evidence and clinical validation could contribute to more personalized and preventive approaches to healthcare.